- July 29, 2021
- Posted by: Stratford Team
- Category: Business
-
Divestiture results from company’s singular focus on additive manufacturing while enabling creation of global leader in medical simulation and training
-
3D Systems will emerge with industry leading scale, breadth of technology, financial performance, and a strong balance sheet for future investment
-
Transaction will complete company’s divestment initiative with priority now on growth and margin expansion as a leader in additive manufacturing
ROCK HILL, S.C., July 28, 2021 (GLOBE NEWSWIRE) — 3D Systems (NYSE:DDD) today announced it has signed a definitive agreement to sell its medical simulation business, Simbionix, to Surgical Science Sweden AB (Nasdaq First North Growth Market:SUS), a leading supplier of virtual reality simulators for medical training, for a purchase price of $305 million, subject to customary closing conditions and adjustments. This action will complete 3D Systems’ initiative to divest non-core businesses in order to focus…
